Oliver Königsbrügge
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Oliver Königsbrügge has a total of 103 co-authors. Here are the top co-authors by number of shared publications:
- Cihan Ay
Medical University of Vienna
24 shared publications Ingrid Pabinger
Medical University of Vienna, Austria
21 shared publicationsMarcus Säemann
Department of Medicine VI, Clinic Ottakring, Vienna, Austria
8 shared publicationsSabine Schmaldienst
Department of Medicine I, Clinic Favoriten, Vienna, Austria
8 shared publications- Florian Posch
Division of Haematology, Department of Internal Medicine, Medical University of Graz, Graz, Austria
7 shared publications Matthias Lorenz
Vienna Dialysis Center, Vienna, Austria
7 shared publications
Latest Publications
- 26 May 2026
- Published by Georg Thieme Verlag KG in Thrombosis and Haemostasis
Comparison of People with Hemophilia A and Patients with Nonvalvular Atrial Fibrillation on Oral Anticoagulation by Thrombin Generation
Recently published guidance on anticoagulation in people with hemophilia (PWH) appraised the literature on whether PWH are naturally anticoagulated: Only two studies compared thrombin generation (TG) in PWH and patients on vitamin K antagonists (VKA), analyzing endogenous thrombin potential (ETP), but were limited by stratifications. We compared TG between PWH A and patients with atrial fibrillation (AF) treated with VKA or direct oral anticoagulants (DOAC). TG was measured by a commercially available assay (Technothrombin), and DOAC levels by mass spectrometry. TG results were compared by equating separate linear regression models, avoiding stratification of the data. We included 565 samples from 110 PWH A, 118 VKA- and 113 DOAC-treated AF patients. TG parameters showed substantial variability among all cohorts, and, accordingly, their relationship with factor (F)VIII, INR, and DOAC levels and ability to differentiate between changes was modest. Importantly, TG curves clustered distinctly between cohorts, and different TG parameters led to varying comparison estimates. FVIII<1 IU/dL in PWH A corresponded to a mean INR-equivalence of 2.3 (95% CI, 2.2–2.5) and 2.0 (1.8–2.2); and a mean DOAC-equivalence of 229.0 (182.1–279.6) and 284.2 (206.2–358.0) ng/mL rivaroxaban, 192.7 (123.0–263.5) and 201.7 (73.8–317.9) ng/mL apixaban, and 313.0 (153.5–448.1) and 242.3 (159.4–328.7) ng/mL dabigatran, using thrombin peak or ETP for estimation, respectively. TG showed substantial variability, differing systematically between PWH A, VKA-treated, and DOAC-treated AF patients. Our data call for caution when using TG to relate the hemostatic potential of PWH A to patients receiving oral anticoagulants and suggest comparisons by individual TG parameters to be overly simplistic.
- 26 May 2026
- Published by Georg Thieme Verlag KG in Thrombosis and Haemostasis
Comparison of People with Hemophilia A and Patients with Nonvalvular Atrial Fibrillation on Oral Anticoagulation by Thrombin Generation
Recently published guidance on anticoagulation in people with hemophilia (PWH) appraised the literature on whether PWH are naturally anticoagulated: Only two studies compared thrombin generation (TG) in PWH and patients on vitamin K antagonists (VKA), analyzing endogenous thrombin potential (ETP), but were limited by stratifications. We compared TG between PWH A and patients with atrial fibrillation (AF) treated with VKA or direct oral anticoagulants (DOAC). TG was measured by a commercially available assay (Technothrombin), and DOAC levels by mass spectrometry. TG results were compared by equating separate linear regression models, avoiding stratification of the data. We included 565 samples from 110 PWH A, 118 VKA- and 113 DOAC-treated AF patients. TG parameters showed substantial variability among all cohorts, and, accordingly, their relationship with factor (F)VIII, INR, and DOAC levels and ability to differentiate between changes was modest. Importantly, TG curves clustered distinctly between cohorts, and different TG parameters led to varying comparison estimates. FVIII<1 IU/dL in PWH A corresponded to a mean INR-equivalence of 2.3 (95% CI, 2.2–2.5) and 2.0 (1.8–2.2); and a mean DOAC-equivalence of 229.0 (182.1–279.6) and 284.2 (206.2–358.0) ng/mL rivaroxaban, 192.7 (123.0–263.5) and 201.7 (73.8–317.9) ng/mL apixaban, and 313.0 (153.5–448.1) and 242.3 (159.4–328.7) ng/mL dabigatran, using thrombin peak or ETP for estimation, respectively. TG showed substantial variability, differing systematically between PWH A, VKA-treated, and DOAC-treated AF patients. Our data call for caution when using TG to relate the hemostatic potential of PWH A to patients receiving oral anticoagulants and suggest comparisons by individual TG parameters to be overly simplistic.
- 2 September 2025
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 20 (12) , 1718-1728
Clonal Hematopoiesis and Cardiovascular Events in Patients with ESKD on Hemodialysis
Key Points: The prevalence of clonal hematopoiesis in patients with ESKD on hemodialysis was 7%. Clonal hematopoiesis was not associated with stroke, myocardial infarction, or venous thromboembolism. Clonal hematopoiesis was associated with vascular access thrombosis. Background: Patients with ESKD on hemodialysis are at high risk for cardiovascular complications. Clonal hematopoiesis (CH), defined as clonal expansion of hematopoietic stem cells due to acquired mutations, was shown to be associated with cardiovascular events, but this association was not yet assessed in patients with impaired kidney function. Methods: Our aim was to investigate the CH-associated mutation prevalence in patients with ESKD on hemodialysis included in the population-based prospective observational Vienna InVestigation of AtriaL Fibrillation and thromboembolism in hemoDIalysis (VIVALDI) study and to assess an association between CH and cardiovascular outcomes. Peripheral blood DNA samples collected at study inclusion were screened for CH-associated mutations. Results: Five hundred seventy patients were analyzed (median age, 66 years [interquartile range [IQR], 55–75]; 37.1% female). The median follow-up time was 39 months (IQR, 35–41). We detected 44 CH-associated variants in 40 patients (7%), most commonly in the gene DNMT3A (43%), TET2 (18%), and TP53 (18%). Patients with CH were older (75 [IQR, 68–80] versus 65 [IQR, 54–74] years, P < 0.001) and had longer cumulative dialysis time (4 [IQR, 1.0–4.0] versus 2 [IQR, 1.9–5.5] years, P = 0.02). CH was not associated with stroke (subdistribution hazard ratio [SHR], 0.25; 95% confidence interval [CI], 0.04 to 1.84), myocardial infarction (SHR, 0.90; 95% CI, 0.20 to 4.13), three-point major adverse cardiovascular events (SHR, 0.65; 95% CI, 0.33 to 1.28), or venous thromboembolism (SHR, 1.68; 95% CI, 0.35 to 8.12) risk. Patients with CH exhibited a higher risk of vascular access thrombosis (SHR, 2.47; 95% CI, 1.34 to 4.56) and patients with non- DNMT3A CH present with a higher all-cause mortality risk (hazard ratio, 1.71; 95% CI, 1.03 to 2.85). Conclusions: Seven percent of patients with ESKD on hemodialysis presented with CH. There was no association between CH and stroke, myocardial infarction, or venous thromboembolism. CH was associated with vascular access thrombosis.
- 2 September 2025
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 20 (12) , 1718-1728
Clonal Hematopoiesis and Cardiovascular Events in Patients with ESKD on Hemodialysis
Key Points: The prevalence of clonal hematopoiesis in patients with ESKD on hemodialysis was 7%. Clonal hematopoiesis was not associated with stroke, myocardial infarction, or venous thromboembolism. Clonal hematopoiesis was associated with vascular access thrombosis. Background: Patients with ESKD on hemodialysis are at high risk for cardiovascular complications. Clonal hematopoiesis (CH), defined as clonal expansion of hematopoietic stem cells due to acquired mutations, was shown to be associated with cardiovascular events, but this association was not yet assessed in patients with impaired kidney function. Methods: Our aim was to investigate the CH-associated mutation prevalence in patients with ESKD on hemodialysis included in the population-based prospective observational Vienna InVestigation of AtriaL Fibrillation and thromboembolism in hemoDIalysis (VIVALDI) study and to assess an association between CH and cardiovascular outcomes. Peripheral blood DNA samples collected at study inclusion were screened for CH-associated mutations. Results: Five hundred seventy patients were analyzed (median age, 66 years [interquartile range [IQR], 55–75]; 37.1% female). The median follow-up time was 39 months (IQR, 35–41). We detected 44 CH-associated variants in 40 patients (7%), most commonly in the gene DNMT3A (43%), TET2 (18%), and TP53 (18%). Patients with CH were older (75 [IQR, 68–80] versus 65 [IQR, 54–74] years, P < 0.001) and had longer cumulative dialysis time (4 [IQR, 1.0–4.0] versus 2 [IQR, 1.9–5.5] years, P = 0.02). CH was not associated with stroke (subdistribution hazard ratio [SHR], 0.25; 95% confidence interval [CI], 0.04 to 1.84), myocardial infarction (SHR, 0.90; 95% CI, 0.20 to 4.13), three-point major adverse cardiovascular events (SHR, 0.65; 95% CI, 0.33 to 1.28), or venous thromboembolism (SHR, 1.68; 95% CI, 0.35 to 8.12) risk. Patients with CH exhibited a higher risk of vascular access thrombosis (SHR, 2.47; 95% CI, 1.34 to 4.56) and patients with non- DNMT3A CH present with a higher all-cause mortality risk (hazard ratio, 1.71; 95% CI, 1.03 to 2.85). Conclusions: Seven percent of patients with ESKD on hemodialysis presented with CH. There was no association between CH and stroke, myocardial infarction, or venous thromboembolism. CH was associated with vascular access thrombosis.
- Open Access
- 18 August 2025
- Published by Elsevier in Thrombosis Research
- Vol. 254, 109431
Antibodies to oxidation-specific epitopes characterize hemodialysis patients protected from cardiovascular events
- 18 August 2025
- Published by Elsevier in Thrombosis Research
- Vol. 254, 109431
Open AccessAntibodies to oxidation-specific epitopes characterize hemodialysis patients protected from cardiovascular events
- Open Access
- 17 July 2025
- Published by Wiley in Haemophilia
- Vol. 31 (5) , 1092-1102
Estimating the Factor VIII‐Equivalent Activity of Emicizumab Using Global Assays of Haemostasis
Background: Emicizumab is a bispecific monoclonal antibody mimicking factor (F) VIII activity and an effective therapy for prophylaxis in people with haemophilia A (PWHA). The FVIII‐equivalent activity (FVIIIeq) of emicizumab remains unknown. Objectives: To estimate FVIIIeq of emicizumab using global assays of haemostasis. Patients/Methods: We sampled plasma from (1) PWHA of all severities and therapeutic regimens and (2) persons with severe haemophilia A on emicizumab. Thrombin generation assay (TGA) and clot formation and lysis assay (CLA) were measured by commercially available (Technothrombin, Technoclone) and turbidimetric assays, respectively. FVIII was measured by a chromogenic (CSA) and emicizumab by a modified one‐stage assay (OSA). Using principal components (PC) or individual parameters as dependent and independent variables in linear regression with (1) FVIII and (2) emicizumab levels, respectively, we estimated FVIIIeq (95% CI) of emicizumab. Results: We collected 253 samples from 110 PWHA and 41 samples from nine individuals on emicizumab prophylaxis. TGA parameters of emicizumab‐treated subjects clustered distinctly, with no correlation amongst samples with only endo‐/exogenous FVIII. Consequently, FVIIIeq varied substantially between parameters: Using individual TGA parameters, endogenous thrombin potential (ETP) and thrombin peak resulted in conversion factors of 0.85 (0.60–1.24) and 0.25 (0.15–0.37) IU/dL FVIIIeq per µg/mL emicizumab, respectively. CLA parameters showed broader overlap, with an FVIIIeq estimate of 0.82 (0.44–1.38). Conclusion: Distinct clustering of emicizumab and FVIII samples in TGA leads to conflicting FVIIIeq estimates between parameters, highlighting systematic limitations and questioning their clinical usefulness. A, possibly conservative, FVIIIeq conversion factor estimate as determined by the thrombin peak could range from 0.15 to 0.37.
- 17 July 2025
- Published by Wiley in Haemophilia
- Vol. 31 (5) , 1092-1102
Open AccessEstimating the Factor VIII‐Equivalent Activity of Emicizumab Using Global Assays of Haemostasis
Background: Emicizumab is a bispecific monoclonal antibody mimicking factor (F) VIII activity and an effective therapy for prophylaxis in people with haemophilia A (PWHA). The FVIII‐equivalent activity (FVIIIeq) of emicizumab remains unknown. Objectives: To estimate FVIIIeq of emicizumab using global assays of haemostasis. Patients/Methods: We sampled plasma from (1) PWHA of all severities and therapeutic regimens and (2) persons with severe haemophilia A on emicizumab. Thrombin generation assay (TGA) and clot formation and lysis assay (CLA) were measured by commercially available (Technothrombin, Technoclone) and turbidimetric assays, respectively. FVIII was measured by a chromogenic (CSA) and emicizumab by a modified one‐stage assay (OSA). Using principal components (PC) or individual parameters as dependent and independent variables in linear regression with (1) FVIII and (2) emicizumab levels, respectively, we estimated FVIIIeq (95% CI) of emicizumab. Results: We collected 253 samples from 110 PWHA and 41 samples from nine individuals on emicizumab prophylaxis. TGA parameters of emicizumab‐treated subjects clustered distinctly, with no correlation amongst samples with only endo‐/exogenous FVIII. Consequently, FVIIIeq varied substantially between parameters: Using individual TGA parameters, endogenous thrombin potential (ETP) and thrombin peak resulted in conversion factors of 0.85 (0.60–1.24) and 0.25 (0.15–0.37) IU/dL FVIIIeq per µg/mL emicizumab, respectively. CLA parameters showed broader overlap, with an FVIIIeq estimate of 0.82 (0.44–1.38). Conclusion: Distinct clustering of emicizumab and FVIII samples in TGA leads to conflicting FVIIIeq estimates between parameters, highlighting systematic limitations and questioning their clinical usefulness. A, possibly conservative, FVIIIeq conversion factor estimate as determined by the thrombin peak could range from 0.15 to 0.37.
- Open Access
- 14 May 2024
- Published by S. Karger AG in Cardiorenal Medicine
- Vol. 14 (1) , 524-532
Telomere Length Is Associated with Increased Risk of Cardiovascular Events in Patients with End-Stage Kidney Disease on Hemodialysis
Introduction: Patients with chronic kidney disease, especially those with end-stage kidney disease (ESKD) on hemodialysis (HD), are at increased risk for cardiovascular disease (CVD), including myocardial infarction and ischemic stroke. A shortening in telomere length, as a parameter for accelerated vascular aging, is an established biomarker for CVD in the general population. We aimed to elucidate the role of telomere length in ESKD patient on HD and its association with cardiovascular outcomes. Methods: Telomere length was measured in a prospective population-based cohort study of prevalent HD patients. DNA was isolated from whole blood, sampled at baseline, and analyzed for telomere length via a qPCR-based approach. The risk for the occurrence of the independently adjudicated three-point major adverse cardiovascular event outcome (myocardial infarction, ischemic stroke, and cardiovascular death) was statistically analyzed considering the competing risk of non-cardiovascular death. Results: In the cohort of 308 patients with ESKD (115 [37.3%] women, median [25th–75th percentile] age: 67.0 [56.8–76.0]), the median telomere length was 1.51 kb (25th–75th percentile 0.6–3.2 kb). The 3P-MACE outcome occurred with an incidence rate of 9.4 per 100 patient-years. Patients with longer telomere length more frequently had vascular nephropathy compared to patients with shorter telomere length. Interestingly, patients in the highest quartile of telomere length had a 1.8-fold increased risk for 3P-MACE (95% CI: 1.051–3.201, p = 0.033), after multivariable adjustment for age, history of stroke, myocardial infarction, venous thromboembolism, presence of heart valve replacement, atrial fibrillation, smoking, anticoagulation, or immunosuppressive use. Conclusion: Surprisingly, in this high-risk cohort of patients with ESKD on HD, longer telomere lengths were associated with increased risk of cardiovascular events.
- 14 May 2024
- Published by S. Karger AG in Cardiorenal Medicine
- Vol. 14 (1) , 524-532
Open AccessTelomere Length Is Associated with Increased Risk of Cardiovascular Events in Patients with End-Stage Kidney Disease on Hemodialysis
Introduction: Patients with chronic kidney disease, especially those with end-stage kidney disease (ESKD) on hemodialysis (HD), are at increased risk for cardiovascular disease (CVD), including myocardial infarction and ischemic stroke. A shortening in telomere length, as a parameter for accelerated vascular aging, is an established biomarker for CVD in the general population. We aimed to elucidate the role of telomere length in ESKD patient on HD and its association with cardiovascular outcomes. Methods: Telomere length was measured in a prospective population-based cohort study of prevalent HD patients. DNA was isolated from whole blood, sampled at baseline, and analyzed for telomere length via a qPCR-based approach. The risk for the occurrence of the independently adjudicated three-point major adverse cardiovascular event outcome (myocardial infarction, ischemic stroke, and cardiovascular death) was statistically analyzed considering the competing risk of non-cardiovascular death. Results: In the cohort of 308 patients with ESKD (115 [37.3%] women, median [25th–75th percentile] age: 67.0 [56.8–76.0]), the median telomere length was 1.51 kb (25th–75th percentile 0.6–3.2 kb). The 3P-MACE outcome occurred with an incidence rate of 9.4 per 100 patient-years. Patients with longer telomere length more frequently had vascular nephropathy compared to patients with shorter telomere length. Interestingly, patients in the highest quartile of telomere length had a 1.8-fold increased risk for 3P-MACE (95% CI: 1.051–3.201, p = 0.033), after multivariable adjustment for age, history of stroke, myocardial infarction, venous thromboembolism, presence of heart valve replacement, atrial fibrillation, smoking, anticoagulation, or immunosuppressive use. Conclusion: Surprisingly, in this high-risk cohort of patients with ESKD on HD, longer telomere lengths were associated with increased risk of cardiovascular events.
- Open Access
- 15 February 2023
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (4) , 3861
Circulatory miR-411-5p as a Novel Prognostic Biomarker for Major Adverse Cardiovascular Events in Patients with Atrial Fibrillation
The risk stratification of patients with atrial fibrillation (AF) for subsequent cardiovascular events could help in guiding prevention strategies. In this study, we aimed at investigating circulating microRNAs as prognostic biomarkers for major adverse cardiovascular events (MACE) in AF patients. We conducted a three-stage nested case–control study within the framework of a prospective registry, including 347 AF patients. First, total small RNA-sequencing was performed in 26 patients (13 cases with MACE) and the differential expression of microRNAs was analyzed. Seven candidate microRNAs with promising results in a subgroup analysis on cardiovascular death were selected and measured via using RT-qPCR in 97 patients (42 cases with cardiovascular death). To further validate our findings and investigate broader clinical applicability, we analyzed the same microRNAs in a subsequent nested case–control study of 102 patients (37 cases with early MACE) by using Cox regression. In the microRNA discovery cohort (n = 26), we detected 184 well-expressed microRNAs in circulation without overt differential expression between the cases and controls. A subgroup analysis on cardiovascular death revealed 26 microRNAs that were differentially expressed at a significance level < 0.05 (three of which with an FDR-adjusted p-value <0.05). We, therefore, proceeded with a nested case–control approach (n = 97) focusing on patients with cardiovascular death and selected, in total, seven microRNAs for further RT-qPCR analysis. One microRNA, miR-411-5p, was significantly associated with cardiovascular death (adjusted HR (95% CI): 1.95 (1.04–3.67)). Further validation (n = 102) in patients who developed early MACE showed similar results (adjusted HR (95% CI) 2.35 (1.17–4.73)). In conclusion, circulating miR-411-5p could be a valuable prognostic biomarker for MACE in AF patients.
- 15 February 2023
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (4) , 3861
Open AccessCirculatory miR-411-5p as a Novel Prognostic Biomarker for Major Adverse Cardiovascular Events in Patients with Atrial Fibrillation
The risk stratification of patients with atrial fibrillation (AF) for subsequent cardiovascular events could help in guiding prevention strategies. In this study, we aimed at investigating circulating microRNAs as prognostic biomarkers for major adverse cardiovascular events (MACE) in AF patients. We conducted a three-stage nested case–control study within the framework of a prospective registry, including 347 AF patients. First, total small RNA-sequencing was performed in 26 patients (13 cases with MACE) and the differential expression of microRNAs was analyzed. Seven candidate microRNAs with promising results in a subgroup analysis on cardiovascular death were selected and measured via using RT-qPCR in 97 patients (42 cases with cardiovascular death). To further validate our findings and investigate broader clinical applicability, we analyzed the same microRNAs in a subsequent nested case–control study of 102 patients (37 cases with early MACE) by using Cox regression. In the microRNA discovery cohort (n = 26), we detected 184 well-expressed microRNAs in circulation without overt differential expression between the cases and controls. A subgroup analysis on cardiovascular death revealed 26 microRNAs that were differentially expressed at a significance level < 0.05 (three of which with an FDR-adjusted p-value <0.05). We, therefore, proceeded with a nested case–control approach (n = 97) focusing on patients with cardiovascular death and selected, in total, seven microRNAs for further RT-qPCR analysis. One microRNA, miR-411-5p, was significantly associated with cardiovascular death (adjusted HR (95% CI): 1.95 (1.04–3.67)). Further validation (n = 102) in patients who developed early MACE showed similar results (adjusted HR (95% CI) 2.35 (1.17–4.73)). In conclusion, circulating miR-411-5p could be a valuable prognostic biomarker for MACE in AF patients.
- Open Access
- 12 December 2022
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 23 (24) , 15770
Antithrombin Activity and Association with Risk of Thrombosis and Mortality in Patients with Cancer
Venous and arterial thromboembolism (VTE/ATE) are common complications in cancer patients. Antithrombin deficiency is a risk factor for thrombosis in the general population, but its connection to risk of cancer-associated thrombosis is unclear. We investigated the association of antithrombin activity levels with risk of cancer-associated VTE/ATE and all-cause mortality in an observational cohort study including patients with cancer, the Vienna Cancer and Thrombosis Study. In total, 1127 patients were included (45% female, median age: 62 years). Amongst these subjects, 110 (9.7%) patients were diagnosed with VTE, 32 (2.8%) with ATE, and 563 (49.9%) died. Antithrombin was not associated with a risk of VTE (subdistribution hazard ratio (SHR): 1.00 per 1% increase in antithrombin level; 95% CI: 0.99–1.01) or ATE (SHR: 1.00; 95% CI: 0.98–1.03). However, antithrombin showed a u-shaped association with the risk of all-cause death, i.e., patients with very low but also very high levels had poorer overall survival. In the subgroup of patients with brain tumors, higher antithrombin levels were associated with ATE risk (SHR: 1.02 per 1% increase; 95% CI: 1.00–1.04) and mortality (HR: 1.01 per 1% increase; 95% CI: 1.00–1.02). Both high and low antithrombin activity was associated with the risk of death. However, no association with cancer-associated VTE and ATE across all cancer types was found, with the exception of in brain tumors.
- 12 December 2022
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 23 (24) , 15770
Open AccessAntithrombin Activity and Association with Risk of Thrombosis and Mortality in Patients with Cancer
Venous and arterial thromboembolism (VTE/ATE) are common complications in cancer patients. Antithrombin deficiency is a risk factor for thrombosis in the general population, but its connection to risk of cancer-associated thrombosis is unclear. We investigated the association of antithrombin activity levels with risk of cancer-associated VTE/ATE and all-cause mortality in an observational cohort study including patients with cancer, the Vienna Cancer and Thrombosis Study. In total, 1127 patients were included (45% female, median age: 62 years). Amongst these subjects, 110 (9.7%) patients were diagnosed with VTE, 32 (2.8%) with ATE, and 563 (49.9%) died. Antithrombin was not associated with a risk of VTE (subdistribution hazard ratio (SHR): 1.00 per 1% increase in antithrombin level; 95% CI: 0.99–1.01) or ATE (SHR: 1.00; 95% CI: 0.98–1.03). However, antithrombin showed a u-shaped association with the risk of all-cause death, i.e., patients with very low but also very high levels had poorer overall survival. In the subgroup of patients with brain tumors, higher antithrombin levels were associated with ATE risk (SHR: 1.02 per 1% increase; 95% CI: 1.00–1.04) and mortality (HR: 1.01 per 1% increase; 95% CI: 1.00–1.02). Both high and low antithrombin activity was associated with the risk of death. However, no association with cancer-associated VTE and ATE across all cancer types was found, with the exception of in brain tumors.
- Open Access
- 30 November 2022
- Published by Springer Nature in Thrombosis Journal
- Vol. 20 (1) , 1-10
Atrial fibrillation and anticoagulation are associated with hospitalisations in patients with end-stage kidney disease on haemodialysis: a prospective population-based cohort study
Background: Patients with end-stage kidney disease on haemodialysis suffer from frequent complications requiring hospitalisation. Atrial fibrillation is a burdensome comorbidity amongst patients on haemodialysis. We aimed to assess frequency, reasons, and duration of hospitalisations in haemodialysis patients and their association with atrial fibrillation and anticoagulation. Methods: Prevalent patients with end-stage kidney disease on haemodialysis were recruited into a prospective cohort study and observed for a median observation time of 3.4 years. Hospitalisations were recorded from discharge letters, medical records, and patient interviews. The association of atrial fibrillation, anticoagulation, and time-in-therapeutic range of vitamin K antagonist treatment with hospitalisations was analysed using negative binomial regression. Results: Out of 625 patients, 238 (38.1%) had atrial fibrillation. Median number of hospitalisations per patient was 3.0 (1.0–5.0). Incidence rate of hospitalisation was 1.7 per patient-year in all and 1.9 in atrial fibrillation patients, median duration per hospitalisation was 7.9 (4.8–12.9) and 8.8 (5.7–13.3) days, respectively. Most frequent reasons for hospitalisation were vascular access complication/intervention (11.7%) and infection/fever (11.4%), while bleeding events comprised 6.0% of all hospitalisations. Atrial fibrillation patients had 27% higher risk of hospitalisation than patients without atrial fibrillation (incidence rate ratio [IRR] 1.27, 95% confidence interval [CI] 1.10–1.47). In atrial fibrillation patients, anticoagulation (enoxaparin or phenprocoumon, 41.6% of AF patients) was associated with increased risk of all-cause (IRR 1.38, 95%CI 1.14–1.69) and bleeding-related hospitalisation (IRR 1.96, 95%CI 1.06–3.63). There was no association between anticoagulation and stroke-related hospitalisation. In atrial fibrillation patients on phenprocoumon, increasing time-in-therapeutic range was associated with decreased risk of all-cause (IRR 0.35, 95%CI 0.14–0.87), but not bleeding-related hospitalisation (IRR 0.13, 95%CI 0.01–1.38). Conclusion: In haemodialysis patients, presence of atrial fibrillation and, among those with atrial fibrillation, anticoagulation were associated with higher risk of all-cause hospitalisation, including bleeding-related hospitalisation in the latter. Increasing time-in-therapeutic range in patients on vitamin K antagonist treatment was associated with decreased risk of all-cause, but not bleeding-related hospitalisation.
- 30 November 2022
- Published by Springer Nature in Thrombosis Journal
- Vol. 20 (1) , 1-10
Open AccessAtrial fibrillation and anticoagulation are associated with hospitalisations in patients with end-stage kidney disease on haemodialysis: a prospective population-based cohort study
Background: Patients with end-stage kidney disease on haemodialysis suffer from frequent complications requiring hospitalisation. Atrial fibrillation is a burdensome comorbidity amongst patients on haemodialysis. We aimed to assess frequency, reasons, and duration of hospitalisations in haemodialysis patients and their association with atrial fibrillation and anticoagulation. Methods: Prevalent patients with end-stage kidney disease on haemodialysis were recruited into a prospective cohort study and observed for a median observation time of 3.4 years. Hospitalisations were recorded from discharge letters, medical records, and patient interviews. The association of atrial fibrillation, anticoagulation, and time-in-therapeutic range of vitamin K antagonist treatment with hospitalisations was analysed using negative binomial regression. Results: Out of 625 patients, 238 (38.1%) had atrial fibrillation. Median number of hospitalisations per patient was 3.0 (1.0–5.0). Incidence rate of hospitalisation was 1.7 per patient-year in all and 1.9 in atrial fibrillation patients, median duration per hospitalisation was 7.9 (4.8–12.9) and 8.8 (5.7–13.3) days, respectively. Most frequent reasons for hospitalisation were vascular access complication/intervention (11.7%) and infection/fever (11.4%), while bleeding events comprised 6.0% of all hospitalisations. Atrial fibrillation patients had 27% higher risk of hospitalisation than patients without atrial fibrillation (incidence rate ratio [IRR] 1.27, 95% confidence interval [CI] 1.10–1.47). In atrial fibrillation patients, anticoagulation (enoxaparin or phenprocoumon, 41.6% of AF patients) was associated with increased risk of all-cause (IRR 1.38, 95%CI 1.14–1.69) and bleeding-related hospitalisation (IRR 1.96, 95%CI 1.06–3.63). There was no association between anticoagulation and stroke-related hospitalisation. In atrial fibrillation patients on phenprocoumon, increasing time-in-therapeutic range was associated with decreased risk of all-cause (IRR 0.35, 95%CI 0.14–0.87), but not bleeding-related hospitalisation (IRR 0.13, 95%CI 0.01–1.38). Conclusion: In haemodialysis patients, presence of atrial fibrillation and, among those with atrial fibrillation, anticoagulation were associated with higher risk of all-cause hospitalisation, including bleeding-related hospitalisation in the latter. Increasing time-in-therapeutic range in patients on vitamin K antagonist treatment was associated with decreased risk of all-cause, but not bleeding-related hospitalisation.
- Open Access
Influence of TP53 Mutation on Survival of Diffuse Large B-Cell Lymphoma in the CAR T-Cell Era
Refractory/relapsed diffuse large B-cell lymphoma (DLBCL) is associated with poor outcome. The clinical behavior and genetic landscape of DLBCL is heterogeneous and still not fully understood. TP53 mutations in DLBCL have been identified as markers of poor prognosis and are often associated with therapeutic resistance. Chimeric antigen receptor T-cell therapy is an innovative therapeutic concept and represents a game-changing therapeutic option by supporting the patient’s own immune system to kill the tumor cells. We investigated the impact of TP53 mutations on the overall survival of refractory/relapsed DLBCL patients treated with comparable numbers of therapy lines. The minimum number of therapy lines was 2 (median 4), including either anti-CD19 CAR T-cell therapy or conventional salvage therapy. A total of 170 patients with DLBCL and high-grade B-cell lymphoma with MYC, BCL2, and/or BCL6 rearrangements (DHL/THL), diagnosed and treated in our hospital between 2000 and 2021, were included. Twenty-nine of them received CAR T-cell therapy. TP53 mutations were found in 10/29 (35%) and 31/141 (22%) of patients in the CAR T-cell and conventional groups, respectively. Among the 141 patients not treated with CAR T cells, TP53 mutation was an independent prognostic factor for overall survival (OS) (median 12 months with TP53 vs. not reached without TP53 mutation, p < 0.005), but in the CAR T cell treated group, this significance could not be shown (median OS 30 vs. 120 months, p = 0.263). The findings from this monocentric retrospective study indicate that TP53 mutation status does not seem to affect outcomes in DLBCL patients treated with CAR T-cell therapy. Detailed evaluation in large cohorts is warranted.
Open AccessInfluence of TP53 Mutation on Survival of Diffuse Large B-Cell Lymphoma in the CAR T-Cell Era
Refractory/relapsed diffuse large B-cell lymphoma (DLBCL) is associated with poor outcome. The clinical behavior and genetic landscape of DLBCL is heterogeneous and still not fully understood. TP53 mutations in DLBCL have been identified as markers of poor prognosis and are often associated with therapeutic resistance. Chimeric antigen receptor T-cell therapy is an innovative therapeutic concept and represents a game-changing therapeutic option by supporting the patient’s own immune system to kill the tumor cells. We investigated the impact of TP53 mutations on the overall survival of refractory/relapsed DLBCL patients treated with comparable numbers of therapy lines. The minimum number of therapy lines was 2 (median 4), including either anti-CD19 CAR T-cell therapy or conventional salvage therapy. A total of 170 patients with DLBCL and high-grade B-cell lymphoma with MYC, BCL2, and/or BCL6 rearrangements (DHL/THL), diagnosed and treated in our hospital between 2000 and 2021, were included. Twenty-nine of them received CAR T-cell therapy. TP53 mutations were found in 10/29 (35%) and 31/141 (22%) of patients in the CAR T-cell and conventional groups, respectively. Among the 141 patients not treated with CAR T cells, TP53 mutation was an independent prognostic factor for overall survival (OS) (median 12 months with TP53 vs. not reached without TP53 mutation, p < 0.005), but in the CAR T cell treated group, this significance could not be shown (median OS 30 vs. 120 months, p = 0.263). The findings from this monocentric retrospective study indicate that TP53 mutation status does not seem to affect outcomes in DLBCL patients treated with CAR T-cell therapy. Detailed evaluation in large cohorts is warranted.
- Open Access
- 21 August 2021
- Published by Elsevier in Journal of Thrombosis and Haemostasis
- Vol. 19 (12) , 2984-2996
Anticoagulation use and the risk of stroke and major bleeding in patients on hemodialysis: From the VIVALDI, a population‐based prospective cohort study
- 21 August 2021
- Published by Elsevier in Journal of Thrombosis and Haemostasis
- Vol. 19 (12) , 2984-2996
Open AccessAnticoagulation use and the risk of stroke and major bleeding in patients on hemodialysis: From the VIVALDI, a population‐based prospective cohort study